K&L Gates Advises Anavex Life Sciences Corp. on US$150 Million Offering

Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing novel treatments for disorders of the central nervous system (CNS), has received advice from K&L Gates LLP about a US$150 million at-the-market (ATM) public offering of common stock. The transaction’s placement agent was TD Securities (USA) LLC.